Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib/Dexamethasone Followed by Lenalidomide in Non-Responders for Untreated Multiple Myeloma
NCT01919086Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2013
- Primary completion
- May 2024
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, dexamethasone, lenalidomide in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2013; status: completed.
02
Drugs
bortezomibdexamethasonelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01919086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01919086.